Study outcome
CHRONIC KIDNEY DISEASE, SECONDARY
The primary endpoint was the change in dnDSA titer at 3 and 12 months after preemptive treatment. The dnDSA titer was determined using either strength of immune-dominant class II dnDSA (MFI) or sum of class II dnDSA (MFI). Immune-dominant dnDSA was defined as DSA with the highest MFI at baseline. The sum of class II dnDSA was calculated by adding the MFI values of all class II dnDSAs. The secondary outcomes were changes in eGFR estimated by the Chronic Kidney Disease Epidemiology Collaboration equation